公开(公告)号：US20240307376A1

公开(公告)日：2024-09-19

申请号：US18670588

申请日：2024-05-21

申请人： Alto Neuroscience, Inc.

发明人： Amit ETKIN ,  Dan SEGAL ,  Wei WU ,  Li SHEN ,  Vinit SHAH ,  Adam SAVITZ

IPC分类号： A61K31/496 ,  A61P25/24 ,  G16H20/10

CPC分类号： A61K31/496 ,  A61P25/24 ,  G16H20/10

摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

公开(公告)号：US20240342165A1

公开(公告)日：2024-10-17

申请号：US18670604

申请日：2024-05-21

申请人： Alto Neuroscience, inc.

发明人： Amit ETKIN ,  Dan SEGAL ,  Wei WU ,  Li SHEN ,  Vinit SHAH ,  Adam SAVITZ

IPC分类号： A61K31/496 ,  A61K45/06 ,  A61P25/24 ,  A61P25/28

CPC分类号： A61K31/496 ,  A61K45/06 ,  A61P25/24 ,  A61P25/28

摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

公开(公告)号：US20240342164A1

公开(公告)日：2024-10-17

申请号：US18670580

申请日：2024-05-21

申请人： Alto Neuroscience, Inc.

发明人： Amit ETKIN ,  Dan SEGAL ,  Wei WU ,  Li SHEN ,  Vinit SHAH ,  Adam SAVITZ

IPC分类号： A61K31/496 ,  A61K9/00 ,  A61P25/28

CPC分类号： A61K31/496 ,  A61K9/0053 ,  A61P25/28

摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino) pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

公开(公告)号：US20240307377A1

公开(公告)日：2024-09-19

申请号：US18670599

申请日：2024-05-21

申请人： Alto Neuroscience, Inc.

发明人： Amit ETKIN ,  Dan SEGAL ,  Wei WU ,  Li SHEN ,  Vinit SHAH ,  Adam SAVITZ

IPC分类号： A61K31/496 ,  A61K9/00 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61P25/24

CPC分类号： A61K31/496 ,  A61K9/0053 ,  A61K31/138 ,  A61K31/15 ,  A61K31/165 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61P25/24

摘要： This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.